-
Carfilzomib Demonstrates Encouraging Response Rates In Patients With Relapsed And/Or Refractory Multiple Myeloma In An Ongoing Phase 2 Study
12/8/2009
Onyx Pharmaceuticals, Inc. recenlty announced results from an ongoing Phase 2 study, known as the 004 study, of the company’s lead proteasome inhibitor, carfilzomib. Results demonstrated promising overall response rates when carfilzomib was administered as a single agent in patients with relapsed and/or refractory multiple myeloma.
-
Novo Nordisk Starts Phase 1 Trial With Oral Insulin Analogue
12/8/2009
Novo Nordisk recently announced that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a USD 2 million payment to Merrion Pharmaceuticals plc, whose GIPET technology is used in the formulation of NN1952.
-
Vetter Dedicates New Facility In Suburban Chicago
12/3/2009
Developing drugs is a slow and expensive process, especially for hard-to-treat diseases such as cancer. Biopharmaceutical companies are continuously seeking ways to accelerate development and control costs.
-
Nuvo Research Announces Organizational Changes
12/3/2009
Nuvo Research Inc., a Canadian drug development company focused on the research and
development of drug products that are delivered to and through the skin using its topical
and transdermal drug delivery technologies, and on the development of its immune
modulating drug candidate WF10, recently announced organizational changes to more
effectively execute the expansion and development of its drug candidate pipeline.
-
Unilife Files Patents For Additional Ready-To-Fill Safety Syringe
12/1/2009
Unilife Medical Solutions Limited recently announced the filing of patent applications in the United States ("US") for a new ready-to-fill syringe product to be marketed as the Unifill Select. Unilife is confident that this new pipeline product, which is to be primarily targeted for use with vaccines, can further expand the Company's ability to penetrate the pharmaceutical market for prefilled syringes.
-
PPD To Acquire BioDuro
11/19/2009
PPD, Inc. (Nasdaq: PPDI) today announced it has signed an agreement to acquire BioDuro LLC, a drug discovery outsourcing company that provides a broad range of integrated services to biopharmaceutical companies. The acquisition will expand PPD's drug development capabilities in China.
-
Higher Dose of Merck's COZAAR (Losartan Potassium Tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study
11/19/2009
In an investigational study, Merck's medicine COZAAR (losartan potassium tablets) 150 mg, administered once daily, significantly reduced the risk of all-cause death or hospitalization due to heart failure compared to a lower 50 mg once daily dose of COZAAR.
-
Merck Expresses Confidence In The Efficacy And Safety Profiles Of ZETIA (ezetimibe) And VYTORIN (ezetimibe/simvastatin) As Effective Medicines For Managing Elevated Cholesterol
11/18/2009
At the American Heart Association meeting recently, Merck & Co., Inc. said it is confident in the safety and efficacy profiles of ZETIA (ezetimibe) and VYTORIN (ezetimibe/simvastatin), and issued the following comment in response to misinterpretation of results from a small 200-patient imaging study called ARBITER 6.
-
Abbott Statement On ARBITER 6 - HALTS Results And Abbott's Niaspan (Niacin Extended-Release)
11/17/2009
Results from the investigator-initiated ARBITER 6 - HALTS study showed patients at high cardiovascular risk had significant regression of atherosclerosis after 8 and 14 months of therapy with Abbott's Niaspan® (niacin extended-release tablets) plus a statin, the study's primary endpoint.
-
Man Sentenced For Sale And Supply Of Controlled And Counterfeit Drugs
11/5/2009
The Medicines and Healthcare products Regulatory Agency (MHRA) discovered more than 86,000 Valium tablets and a further 11,500 medicinal products in an undercover investigation into Gami’s illegal online dealing.
